Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials

Clinical Cancer Research

Volumn 19, Issue 10, 2013, Pages 2637-2645

  Zhang, Jenny J ^a,d   Zhang, Lijun ^a   Chen, Huanyu ^a   Murgo, Anthony J ^b   Dodd, Lori E ^c   Pazdur, Richard ^b   Sridhara, Rajeshwari ^a,b  

^a Division of Biometrics Office of Biostatistics Office of Translational Sciences   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST METASTASIS; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METASTATIC COLORECTAL CANCER; METHODOLOGY; ONCOLOGY; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; REGISTRATION; REVIEW; SOFT TISSUE SARCOMA; TUMOR GROWTH; ALGORITHM; ANALOGS AND DERIVATIVES; BIOASSAY; CARCINOID TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; MEDICAL AUDIT; NEOPLASMS; OUTCOME ASSESSMENT; PATHOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; SARCOMA; STATISTICAL BIAS;

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; RIDAFOROLIMUS;

ALGORITHMS; BIAS (EPIDEMIOLOGY); CARCINOID TUMOR; CLINICAL AUDIT; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SARCOMA; SIROLIMUS;

EID: 84878031625     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3364     Document Type: Review

References (8)

1. Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, et al. Lessons learned from independent central review. Eur J Cancer 2009;45:268-74.
2. Dodd LE, Korn EL, Freidlin B, Jaffe CC, Rubinstein LV, Dancey J, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 2008;26:3791-6.
3. Amit O, Mannino F, Stone AM, Bushnell W, Denne J, Helterbrand J, et al. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. Eur J Cancer 2011;47: 1772-8.
4. Zhang JJ, Chen H, He K, Tang S, Justice R, Keegan P, et al. Evaluation of blinded independent central review of tumor progression in oncology clinical trials: a meta-analysis. Drug Inf J 2013;47: 167-74.
5. Dodd LE, Korn EL, Freidlin B, Gray R, Bhattacharya S. An audit strategy for progression-free survival. Biometrics 2011;67: 1092-9.
6. Oncologic Drug Advisory Committee-everolimus for carcinoid tumors. [cited 2011 Apr 12]. Available from: http://www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm235829.htm
7. Oncologic Drug Advisory Committee-ridaforolimus for STS. [cited 2012 Mar 20]. Available from: http://www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisory Committee/ucm285400.htm
8. Oncologic Drug Advisory Committee-evaluation of radiologic review of PFS in non-hematologic malignancies. [cited 2012 Jul 24]. Available from: http://www.fda.gov/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/ OncologicDrugsAdvisoryCommittee/ucm285400.htm